ILUSTRASI. Merck & Co is in advanced talks to buy cancer-focused biotech company Seagen Inc in a deal that could be worth roughly US$ 40 billion. REUTERS/Mike Blake/Illustration/File Photo GLOBAL BUSINESS WEEK AHEAD - SEARCH GLOBAL BUSINESS 15 MAY FOR ALL IMAGES
Sumber: Wall Street Journal,Reuters | Editor: Anastasia Lilin Yuliantina
KONTAN.CO.ID - Drugmaker Merck & Co is in advanced talks to buy cancer-focused biotech company Seagen Inc in a deal that could be worth roughly US$ 40 billion or more. The Wall Street Journal reported on Wednesday.
The companies are discussing a price above US$ 200 a share for Seagen, the report said, citing people familiar with the matter.
Hanya Rp 5.000 untuk membaca artikel ini.
BELI SEKARANG
